News

Why Hims & Hers Stock Is Crashing, and Is It a Buying Opportunity?
Novo Nordisk (NYSE: NVO) severed its partnership with Hims & Hers (NYSE: HIMS), arguing that the company breached the ...
Stocks on the Move: Hims & Hers Health and JetBlue
The Investment Committee discuss their strategy on some stocks on the move today. California Democrats stage internal war ...
Long Island experts weigh in after Novo Nordisk ends deal with Hims & Hers over weight loss meds
Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...
Why Hims & Hers Health Stock Is Crashing Today
The loss of its ability to sell Wegovy is a significant hit to Hims & Hers' business. The massive drop today in its stock ...
Novo, Hims & Hers engage in war of words after Wegovy deal falls apart
Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending ...
Hims & Hers: Panic Sell Or Opportunistic Buy?
The breakup between Hims & Hers and Novo Nordisk has hit HIMS stock hard with a 35% crash. Click here for a full investment ...
TMCnet2h
HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press ...
Hims & Hers appoints former Robinhood exec Dheerja Kaur as first CPO
Investing.com -- Hims & Hers Health (NYSE: HIMS) has named Dheerja Kaur as its first-ever Chief Product Officer, according to an announcement from CEO Andrew Dudum.